SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood. 1995; 86: 24632474.
  • 2
    Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia. 2002; 16: 10151027.
  • 3
    Kosmas C, Stamatopoulos K, Stavroyianni N, Tsavaris N, Papadaki T. Anti-CD20 based therapy of B cell lymphoma: state of the art. Leukemia. 2002; 16: 20042015.
  • 4
    Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma. 2004; 45: 205219.
  • 5
    Robak T. Rituximab plus purine nucleoside analogs in the treatment of indolent lymphoid malignancies. Am J Cancer. 2005; 4: 279292.
  • 6
    Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity to either drug alone. Br J Haematol. 2001; 114: 800809.
  • 7
    Smolewski P, Szmigielska-Kapłon A, Cebula B, et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2005; 46: 87100.
  • 8
    Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 40704078.
  • 9
    Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 40794088.
  • 10
    Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005; 23: 694704.
  • 11
    Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood. 2005; 105: 4953.
  • 12
    Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006; 24: 15751581.
  • 13
    Robak T, Smolewski P, Urbańska-Rys H, et al. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma. 2004; 45: 937944.
  • 14
    Robak T. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies. Drugs Aging. 2005; 22: 9831012.
  • 15
    Weiss MA, Masiak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003; 21: 12781284.
  • 16
    Kay E, Geyer SN, Lin T, et al. Combination chemotherapy with pentostatin, cyclophosphamide and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated chronic lymphocytic leukemia. Blood. 2004; 104( Suppl 1): 100a. Abstract 339.
  • 17
    Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 38353849.
  • 18
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 49904997.
  • 19
    Rai KR, Savitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46: 219234.
  • 20
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas NCI sponsored International Working Group. J Clin Oncol. 1999; 17: 12441253.
  • 21
    Duffy DR, Santner TJ. Confidence intervals binomial parameter based on multistage tests. Biometrics. 1987; 47: 8193.
  • 22
    Robak T, Gora-Tybor J, Krykowski E, et al. Activity of 2-chlorodeoxyadenosine (cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1997; 26: 99105.
  • 23
    Hoffman M, Tallman MS, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol. 1994; 12: 788792.
  • 24
    Liliemark J, Porwit A, Juliusson G. Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1997; 25: 313318.
  • 25
    Laurencet FM, Zulian GB, Guetty-Alberto M, Iten PA, Betticher DC, Alberto P. Cladribine with cyclophosphamide and prednisone in the management of low grade lymphoproliferative malignancies. Br J Cancer. 1999; 79: 12151219.
  • 26
    Robak T, Gora-Tybor J, Lech-Maranda E, Blonski JZ, Kasznicki M. Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Haematol. 2001; 66: 188194.
  • 27
    Robak T, Szmigielska-Kapłon A, Blonski JZ, Kasznicki M, Chojnowski K. Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies. Chemotherapy. 2005; 51: 247251.
  • 28
    Savage DG, Cohen NS, Hesdorffer CS, et al. Combined flu darabine and rituximab for low grade lymphoma or chronic lymphocytic leukemia. Leuk Lymphoma. 2003; 44: 477481.
  • 29
    Forstpointer R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood. 2004; 104: 30643071.
  • 30
    Di Bella N, Reynolds C, Faragher D, Muscato J, Boehm KA, Asmar L. An open-label pilot study of pentostatin, mitoxantrone and rituximab in patients with previously untreated Stage III or IV, low-grade non-Hodgkin lymphoma. Cancer. 2005; 103: 978984.
  • 31
    Del Poeta G, Del Principe MI, Consalvo MA, et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70 negative chronic lymphocytic leukemia. Cancer. 2005; 104: 27432752.
  • 32
    Drapkin R, Di Bella NJ, Faragher DC, et al. Results of Phase II multicenter trial of pentostatin and rituximab in patients with low-grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen. Clin Lymphoma. 2003; 4: 169175.
  • 33
    Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood. 2005; 105: 14171423.
  • 34
    Tondini C, Balzarotti M, Rampinelli I, et al. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a Phase II randomized study. Ann Oncol. 2000; 11: 231233.
  • 35
    Karlsson K, Stromberg M, Johnsson V, et al. Cladribine (CdA) or fludarabine (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment in chronic lymphocytic leukemia: first interim analysis of data from the international randomized Phase III trial. Blood. 2004; 104( Suppl 1): 1111. Abstract 3470.
  • 36
    Robak T, Blonski JZ, Gora-Tybor J, et al. Randomized comparison of cladribine with cyclophosphamide and fludarabine with cyclophosphamide in previously untreated progressive and symptomatic chronic lymphocytic leukemia: the interim analysis of PALG CLL3 trial. Blood. 2005; 106( Suppl 2): 600a. Abstract 2121.
  • 37
    Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006; 107: 885891.
  • 38
    Robak T, Blonski JZ, Gora-Tybor J, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of prospective multicenter randomized trial of the Polish Adult Leukemia Group. (PALG CLL2). Blood. 2006; 108: 473479.